Importantly, these findings revealed that the CpG sites differed from one STS subtype to another, suggesting that the methylation modification of certain CpG sites may be a critical event for tissue-specific expression of PLAGL1. This may constitute a specific methylation signature, possibly resulting from a difference in tumor microenvironment [37] or differentiation lineage. The gene discussed is PLAGL1; the disease is neoplasm.